Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium

References

• Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–1607. doi:10.1056/NEJMoa1008232.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical Aortic-Valve replacement in Intermediate-Risk patients. N Engl J Med. 2016;374(17):1609–1620. doi:10.1056/NEJMoa1514616.
   PubMed Web of Science ®Google Scholar
• Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77(9):1149–1161. doi:10.1016/j.jacc.2020.12.052.
   PubMed Web of Science ®Google Scholar
• Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve replacement with a Balloon-Expandable valve in Low-Risk patients. N Engl J Med. 2019;380(18):1695–1705. doi:10.1056/NEJMoa1814052.
   PubMed Web of Science ®Google Scholar
• Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632. doi:10.1093/eurheartj/ehab395.
   PubMed Web of Science ®Google Scholar
• Gilard M, Eltchaninoff H, Iung B, et al. Cost-Effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. Value Health. 2022;25(4):605–613. doi:10.1016/j.jval.2021.10.003.
   PubMed Web of Science ®Google Scholar
• Mennini FS, Meucci F, Pesarini G, et al. Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients. Int J Cardiol. 2022;357:26–32. doi:10.1016/j.ijcard.2022.03.034.
   PubMed Web of Science ®Google Scholar
• Pinar E, García de Lara J, Hurtado J, et al. Cost-effectiveness analysis of the SAPIEN 3 transcatheter aortic valve implant in patients with symptomatic severe aortic stenosis. Rev Esp Cardiol (English ed). 2022;75(4):325–333. doi:10.1016/j.recesp.2021.02.006.
   PubMed Web of Science ®Google Scholar
• Kuck KH, Leidl R, Frankenstein L, et al. Cost-Effectiveness of SAPIEN 3 transcatheter aortic valve implantation versus surgical aortic valve replacement in german severe aortic stenosis patients at low surgical mortality risk. Adv Ther. 2023;40(3):1031–1046. doi:10.1007/s12325-022-02392-y.
   PubMed Web of Science ®Google Scholar
• Kuck K-H, Bleiziffer S, Eggebrecht H, et al. Consensus paper of the german society of cardiology (DGK) and the german society of thoracic, cardiovascular and vascular surgery (DGTHG) on catheter-assisted aortic valve implantation (TAVI) 2020. Kardiologe. 2020;14(3):182–204. doi:10.1007/s12181-020-00398-w.
   Web of Science ®Google Scholar
• Federale Overheidsdienst Sociale Zekerheid. Ministerieel besluit tot wijziging van hoofdstuk "F. Heelkunde op de thorax en cardiologie" van de lijst en van de nominatieve lijsten, gevoegd als bijlagen 1 en 2 bij het koninklijk besluit van 25 juni 2014 tot vaststelling van de procedures, termijnen en voorwaarden inzake de tegemoetkoming van de verplichte verzekering voor geneeskundige verzorging en uitkeringen in de kosten van implantaten en invasieve medische hulpmiddelen. 2023. http://www.ejustice.just.fgov.be/eli/besluit/2023/03/27/2023010148/staatsblad
   Google Scholar
• Le Chapitre F, Service Public Federal Securite Sociale. Arrêté ministériel modifiant Chirurgie thoracique et cardiologie » de la liste et les listes nominatives jointes comme annexes 1 et 2 à l‘arrêté royal du 25 juin 2014 fixant les procédures, délais et conditions en matière d‘intervention de l‘assurance obligatoire soins de santé et indemnités dans le coût des implants et des dispositifs médicaux invasifs. 2023. http://www.ejustice.just.fgov.be/eli/arrete/2023/03/27/2023010148/moniteur
   Google Scholar
• Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018;39(28):2635–2642. doi:10.1093/eurheartj/ehy107.
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Van De Sande S, et al. Belgian guidelines for economic evaluations and budget impact analyses: second edition. KCE Reports. 2012.
   Google Scholar
• Szende A, Janssen B, Cabases J. Self-Reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer Copyright; 2014.
   Google Scholar
• SAFE. Stroke Alliance For Europe. The burden of stroke in Belgium. 2017. https://www.safestroke.eu/wp-content/uploads/2017/12/SAFE_STROKE_BELGIUM.pdf
   Google Scholar
• Vermond RA, Geelhoed B, Verweij N, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a Community-Based study from The Netherlands. J Am Coll Cardiol. 2015;66(9):1000–1007. doi:10.1016/j.jacc.2015.06.1314.
   PubMed Web of Science ®Google Scholar
• Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards perimount valve in aortic position. Ann Thorac Surg. 2015;99(3):831–837. doi:10.1016/j.athoracsur.2014.09.030.
   PubMed Web of Science ®Google Scholar
• StatBel. Mortality tables and life expectancy. 2022. https://statbel.fgov.be/sites/default/files/files/documents/bevolking/5.4%20Sterfte%2C%20levensverwachting%20en%20doodsoorzaken/5.4.3%20Sterftetafels%20en%20levensverwachting/sterftetafelsAE.xls
   Google Scholar
• Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. doi:10.1136/bmj.i4482.
   PubMed Web of Science ®Google Scholar
• Dennis MS, Burn JP, Sandercock PA, et al. Long-term survival after first-ever stroke: the oxfordshire community stroke project. Stroke. 1993;24(6):796–800. doi:10.1161/01.str.24.6.796.
   PubMed Web of Science ®Google Scholar
• APR-DRG. TCT (Technical cell for the processing of the data related to the hospitals), "National database medical diagnosis/care & cost - Financial feedback by pathology: APR-DRG. 2020. https://tct.fgov.be/webetct/etct-web/national_data?lang=nl&menuSelected=apr_drg&selectedSideMenu=default&reset=true
   Google Scholar
• Ishak KJ, Stolar M, Hu MY, et al. Accounting for the relationship between per diem cost and LOS when estimating hospitalization costs. BMC Health Serv Res. 2012;12(1):439. doi:10.1186/1472-6963-12-439.
   PubMedGoogle Scholar
• De Smedt DM, Elseviers MM, Lins RL, et al. Economic evaluation of different treatment modalities in acute kidney injury. Nephrol Dial Transplant. 2012;27(11):4095–4101. doi:10.1093/ndt/gfs410.
   PubMed Web of Science ®Google Scholar
• Elseviers MM, Lins RL, Van der Niepen P, et al. Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury. Crit Care. 2010;14(6):R221. doi:10.1186/cc9355.
   PubMed Web of Science ®Google Scholar
• Neyt M, Stroobandt S, Obyn C, et al. Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime markov model. BMJ Open. 2011;1(2):e000276–e000276. doi:10.1136/bmjopen-2011-000276.
   PubMed Web of Science ®Google Scholar
• Pirson M, Di Pierdomenico L, Gusman J, et al. Evaluation of the cost of atrial fibrillation during emergency hospitalization. Acta Cardiol. 2013;68(5):469–474. doi:10.1080/ac.68.5.2994469.
   PubMed Web of Science ®Google Scholar
• Van Brabandt H, Neyt M, Devos C. Catheter ablation of atrial fibrillation. Health Technology Assessment (HTA). Brussels. Belgian Health Care Knowledge Centre (KCE). KCE Reports 184. 2012. https://kce.fgov.be/en/publications/all-reports/catheter-ablation-of-atrial-fibrillation
   Google Scholar
• Dewilde S, Annemans L, Lloyd A, et al. The combined impact of dependency on caregivers, disability, and coping strategy on quality of life after ischemic stroke. Health Qual Life Outcomes. 2019;17(1):31. doi:10.1186/s12955-018-1069-6.
   PubMedGoogle Scholar
• Neyt M, Van Brabandt H, Van De Sande S, et al. Transcatheter Aortic Valve Implantation (TAVI): a Health Technology Assessment Update. Health Technology Assessment (HTA). Brussels. Belgian Health Care Knowledge Centre (KCE). KCE Report 163. 2011. https://kce.fgov.be/en/publications/all-reports/transcatheter-aortic-valve-implantation-tavi-a-health-technology-assessment-update
   Google Scholar
• RIZIV. Analysis of the distribution and evolution of medical practices in Belgium, in terms of volume and expenditure per insured, for 2021 - Pacemaker (1st implant). 2022.
   Google Scholar
• Lanitis T, Cotté FE, Gaudin AF, et al. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17(8):587–598. doi:10.3111/13696998.2014.923891.
   PubMedGoogle Scholar
• Hettle R, Wouters H, Ayres J, et al. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respir Med. 2012;106(12):1722–1733. doi:10.1016/j.rmed.2012.09.006.
   PubMed Web of Science ®Google Scholar
• Makkar RR, Thourani VH, Mack MJ, et al. Five-Year outcomes of transcatheter or surgical Aortic-Valve replacement. N Engl J Med. 2020;382(9):799–809. doi:10.1056/NEJMoa1910555.
   PubMed Web of Science ®Google Scholar
• Beyersdorf F, Bauer T, Freemantle N, et al. Five-year outcome in 18 010 patients from the german aortic valve registry. Eur J Cardiothorac Surg. 2021;60(5):1139–1146. doi:10.1093/ejcts/ezab216.
   PubMed Web of Science ®Google Scholar
• Jacobs MS, de Jong LA, Postma MJ, et al. Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. Eur J Health Econ. 2018;19(7):957–965. doi:10.1007/s10198-017-0942-2.
   PubMed Web of Science ®Google Scholar
• Rapoport J, Teres D, Zhao Y, et al. Length of stay data as a guide to hospital economic performance for ICU patients. Med Care. 2003;41(3):386–397. doi:10.1097/01.MLR.0000053021.93198.96.
   PubMed Web of Science ®Google Scholar
• Lutz M, Messika-Zeitoun D, Rudolph TK, et al. Differences in the presentation and management of patients with severe aortic stenosis in different european centres. Open Heart. 2020;7(2):e001345. doi:10.1136/openhrt-2020-001345.
   PubMed Web of Science ®Google Scholar
• Mylotte D, Osnabrugge RL, Martucci G, et al. Adoption of transcatheter aortic valve implantation in Western Europe. Interv Cardiol. 2014;9(1):37–40. doi:10.15420/icr.2011.9.1.37.
   PubMedGoogle Scholar
• Nguyen V, Michel M, Eltchaninoff H, et al. Implementation of transcatheter aortic valve replacement in France. J Am Coll Cardiol. 2018;71(15):1614–1627. doi:10.1016/j.jacc.2018.01.079.
   PubMed Web of Science ®Google Scholar
• Stachon P, Zehender M, Bode C, et al. Development and in-Hospital mortality of transcatheter and surgical aortic valve replacement in 2015 in Germany. J Am Coll Cardiol. 2018;72(4):475–476. doi:10.1016/j.jacc.2018.04.077.
   PubMed Web of Science ®Google Scholar
• HAS-Sante. SAPIEN 3 treatment of severe symptomatic aortic stenosis in low-risk surgical patients in France 2021. https://www.has-sante.fr/upload/docs/application/pdf/2021-04/sapien3_9022021_avis_economique_vf2.pdf
   Google Scholar
• NIPH (Norwegian Institute of Public Health). Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment. 2021. https://www.fhi.no/en/publ/2021/TAVI-vs-SAVR-for-patients-with-severe-aortic-stenosis-and-low-surgical-risk-and-across-surgical-risk-groups/
   Google Scholar
• HIQA (Health Information and Quality Authority). Health Technology Assessment of transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis at low and intermediate risk of surgical complications. 2019. https://www.hiqa.ie/sites/default/files/2019-12/TAVI_HTA.pdf
   Google Scholar
• Zhou JY, Liew D, Duffy SJ, et al. Cost-Effectiveness of transcatheter versus surgical aortic valve replacement in Low-Risk patients with severe aortic stenosis. Heart Lung Circ. 2021;30(4):547–554. doi:10.1016/j.hlc.2020.09.934.
   PubMed Web of Science ®Google Scholar
• Tam DY, Azizi PM, Fremes SE, et al. The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):556–563. doi:10.1093/ehjqcco/qcaa058.
   PubMed Web of Science ®Google Scholar
• Beyersdorf F, Vahanian A, Milojevic M, et al. Erratum to: 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2022;61(4):964–964. doi:10.1093/ejcts/ezab557.
   PubMed Web of Science ®Google Scholar
• Durand E, Tchétché D, Leroux L, et al. Multicenter cluster randomized controlled study evaluating the efficacy of an intervention aimed at reducing the length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II study. EuroPCR. Paris, France. 2023.
   Google Scholar
• Frank D, Durand E, Lauck S, et al. BENCHMARK: a streamlined TAVI pathway with uncompromised safety in 28 european centers. EuroPCR. Paris, France. 2023.
   Google Scholar
• Pibarot P, Ternacle J, Jaber WA, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 trial. J Am Coll Cardiol. 2020;76(16):1830–1843. doi:10.1016/j.jacc.2020.08.049.
   PubMed Web of Science ®Google Scholar